New Zealand firm Greenfern Industries has joined forces with medicinal cannabis supplier Ampyl Sciences to export its flower to the EU and UK.
The first batch of the product, cultivated by Greenfern and exported under Ampyl’s CannFX brand, has already been shipped.
The move follows Greenfern’s sale of its second harvested batch to Ampyl Sciences under a multi-year supply agreement for its medicinal cannabis flower.
Greenfern said the export venture opens new avenues for revenue and ensures consistent cash flow for the Taranaki-headquartered company.
With increased production capacity at its recently commissioned cultivation facility, it added is poised to meet the growing demand for medicinal cannabis domestically and overseas.
Managing Director Dan Casey said the company’s foray into the EU and UK would enable it to enter “some of the largest markets globally”.
Greenfern’s cultivation productivity has increased by more than 50 per cent since its facility was commissioned in August last year, with subsequent harvests expected to deliver a substantial increase in volume.
Having already started exporting medicinal cannabis to Germany in 2022, and the UK last year, Ampyl already has traction in those markets.
